Phenazopyridine
Phenazopyridine hydrochloride is the only FDA-approved urinary-tract-specific analgesic — an azo dye excreted in the urine that acts topically on the urothelium to blunt the pain, burning, urgency, and frequency caused by infection, trauma, endoscopic instrumentation, catheter passage, or the passage of sounds and bougies.[1][2] For the reconstructive urologist and urogynecologist it is a short-term bridge analgesic — useful in the 24–48 hours before empiric antibiotics take hold for a symptomatic UTI, after office cystoscopy, following dilation or DVIU, after intravesical chemodenervation with onabotulinumtoxinA, and around urethral-sound or transurethral-catheter procedures — never a substitute for definitive therapy. The class sits in "legacy" not because it has fallen out of favor, but because its evidence base is thin by modern standards; it remains in wide use because no better urothelium-selective analgesic exists.
For the broader analgesic landscape — NSAIDs, opioids, adjuncts — see NSAIDs & analgesics. For the central-neuromodulation comparators, see Gabapentinoids, SNRIs, and TCAs.
Mechanism of Action
Phenazopyridine is an azo dye — its pharmacokinetic properties have not been formally characterized, but roughly 66% of an oral dose is excreted unchanged in the urine, where it exerts a topical analgesic effect on the urothelial mucosa.[1][2] The precise molecular target was historically unknown.
A 2023 electrophysiology study (Luyts et al, Eur J Pharmacol) identified TRPM8 channel inhibition as the likely basis for its urinary-tract-selective analgesic effect.[3]
- TRPM8 — a cold- and menthol-sensitive cation channel expressed on bladder afferent C- and Aδ-fibers, upregulated in painful bladder disorders (bladder pain syndrome / interstitial cystitis, OAB).
- Phenazopyridine inhibits TRPM8 rapidly and reversibly with IC₅₀ of 2–10 μM — urinary concentrations achieved with standard dosing fall squarely within this range.
- At 10 μM it does not significantly block other pain-relevant TRP channels (TRPA1, TRPV1, TRPM3), suggesting relative selectivity.
- This is consistent with the clinical observation that phenazopyridine works locally on the urothelium and does not produce systemic analgesia.
The TRPM8-inhibition model is mechanistically satisfying but has not yet been translated into validated biomarkers or predictive response data.
Agents in This Class
| Generic Name | Brand Name(s) | Strength | Availability | Notes |
|---|---|---|---|---|
| Phenazopyridine HCl | Pyridium, Azo-Standard, Uristat, AZO Urinary Pain Relief | 95 mg, 97.5 mg (OTC); 100 mg, 200 mg (Rx) | OTC & Rx | Azo dye; orange-red urinary discoloration is universal and expected |
Pyridium (as a branded product) has been discontinued in the US but the generic remains broadly available at the same strengths.
Indications in Reconstructive Urology
Phenazopyridine is purely symptomatic — it neither treats infection nor modifies disease.[1][2] Its role in reconstructive and functional practice is narrow and tactical:
| Scenario | Rationale |
|---|---|
| Symptomatic UTI, first 24–48 h of empiric antibiotics | Bridges analgesia while the antibacterial takes effect; reduces need for NSAIDs or opioids[1][2][4] |
| Post-office cystoscopy / flexible ureteroscopy | Blunts the characteristic 24-h post-procedure dysuria |
| Post-urethral dilation or DVIU | Short-term analgesia during the high-irritation window |
| After passage of sounds, bougies, or transurethral catheter placement | Listed indication on the FDA label[1][2] |
| Recurrent-UTI patients between cultures | Symptomatic control while awaiting susceptibilities — does not substitute for culture-directed therapy per AUA/CUA/SUFU rUTI guidance[5] |
| Post-intravesical onabotulinumtoxinA | Off-label bridge for the transient dysuria many patients report in the first 1–2 days |
| IC/BPS flares | Occasional symptomatic adjunct — no guideline-grade evidence; limited by the 2-day rule when combined with antibacterials |
Out of scope: phenazopyridine is not an alternative to antibiotics for UTI, not a chronic-use analgesic, and not a treatment for inflammatory or neoplastic urothelial disease.
Dosing & Administration
| Formulation | Dose | Frequency | Key rule |
|---|---|---|---|
| 200 mg tablet | 1 tablet | TID after meals | Discontinue when symptoms controlled[1][2] |
| 100 mg tablet | 2 tablets | TID after meals | Equivalent to 200 mg TID[1][2] |
| OTC (95 / 97.5 mg) | Per product labeling | TID | Generally ≤ 2 days of use recommended |
The 2-day rule: when given concomitantly with an antibacterial for UTI, duration should not exceed 2 days — there is no evidence of added benefit beyond that and prolonged exposure increases the risk of accumulation-related adverse effects.[1][2]
Phenazopyridine should always be paired with definitive therapy and discontinued as soon as symptoms are controlled. Empiric chronic use masks infection, delays culture-directed treatment, and exposes the patient to accumulation risk.
Contraindications & Precautions
Absolute contraindications[1][2]
- Renal insufficiency — 66% of a dose is excreted unchanged, so impaired clearance leads to drug accumulation and disproportionate toxicity
- Hypersensitivity to phenazopyridine
- Advanced age — age-related decline in eGFR effectively reduces clearance
- G6PD deficiency — predisposes to oxidative Heinz-body hemolytic anemia
- Sulfur sensitivity — the product does not contain sulfur but rare sulfur-type reactions have been reported
- Pregnancy — formerly Category B; no adequate human studies, use only if clearly indicated
- Nursing — no data on human-milk excretion
Clinical warning signs that mandate discontinuation[1][2]
- Yellowish tinge of skin or sclera (suggests accumulation due to impaired renal excretion)
- Any systemic dermatologic or hematologic reaction
Adverse Reactions & Overdose
| Category | Details |
|---|---|
| Common | Headache, rash, pruritus, mild GI upset[1][2] |
| Hematologic (overdose / renal impairment) | Methemoglobinemia (treat with methylene blue 1–2 mg/kg IV or ascorbic acid 100–200 mg PO); Heinz-body hemolytic anemia with "bite cells" (degmacytes) on smear in chronic overdose[1][2] |
| Renal / hepatic | Impairment or failure — usually hypersensitivity-driven[1][2] |
| Dermatologic | Yellow skin/scleral tinge (accumulation); rare anaphylactoid reactions[1][2] |
| Neoplasia (animal) | Long-term dosing induced neoplasms in rat large intestine and mouse liver; no association with human neoplasia has been demonstrated, but adequate epidemiology is lacking[1][2] |
Methylene-blue paradox: the treatment for phenazopyridine-induced methemoglobinemia is itself a dye the reconstructive urologist may recognize from intraoperative use — see Methylene blue. It is relatively contraindicated in G6PD deficiency, where ascorbic acid is the preferred antidote.
Perioperative Considerations
- Stop before any planned surgery. There is no perioperative indication that justifies continuing the drug — it has no disease-modifying effect and complicates interpretation of postoperative urine.
- Urinalysis interference — phenazopyridine's orange-red color invalidates any urinalysis based on spectrometry or colorimetric strips (glucose, ketones, bilirubin, leukocyte esterase, nitrite).[1][2] If a post-op UA is needed, stop the drug at least 24 hours in advance and confirm with microscopy / culture.
- Clothing and contact-lens staining — counsel patients specifically about contact-lens staining; soft lenses can be permanently discolored.[1][2]
- Post-endoscopic or post-dilation use is appropriate short-term analgesia but does not replace intravesical lidocaine, NSAIDs, or local-anesthetic-impregnated gel during the procedure itself.
- Catheter aftercare — reasonable in the first 24–48 hours after a difficult catheterization, particularly after urethral instrumentation through an atrophic or strictured urethra.
Evidence Summary
| Indication | Evidence Level | Key Source | Notes |
|---|---|---|---|
| Acute symptomatic UTI bridge analgesia | Label-based / expert | FDA label[1][2]; Zelenitsky-Zhanel review[4] | 2-day limit with antibacterials; no RCT demonstrating added benefit beyond analgesia |
| Post-procedural dysuria (cystoscopy, dilation, catheter, sounds) | Label-based / expert | FDA label[1][2] | On-label indication; no high-quality comparative trials |
| TRPM8 mechanism | Preclinical (in vitro) | Luyts 2023[3] | Plausible molecular basis; not a clinical biomarker |
| Chronic use / disease modification | Not supported | FDA label[1][2] | Discontinue when symptoms controlled |
| rUTI prevention | Not an indication | AUA/CUA/SUFU 2022[5] | Symptomatic only — see UTI suppressive & prophylactic |
Practical Pearls
- "200 mg TID × 2 days" is the only dose the busy clinic should need to remember — anything longer invites trouble.
- Counsel about urine color up front. Patients who see orange-red urine without warning present to the ED thinking they are bleeding; patients who are warned are unconcerned.
- Warn about contact lenses. Soft lenses can be permanently stained — recommend glasses for the duration of therapy.
- Check renal function before prescribing in the elderly — the most common preventable harm is accumulation in unrecognized CKD.
- Ask about G6PD in patients of African, Mediterranean, or Southeast Asian ancestry before prescribing a course longer than the standard 2-day bridge.
- Do not chase a UA after starting it — the dye invalidates strip-based testing; rely on culture.
- The 2-day rule exists for a reason. There is no evidence of additional benefit beyond 48 hours, and every additional day raises the risk of methemoglobinemia, hemolysis, and hepatorenal injury — particularly in older patients.
- It is not a treatment for IC/BPS. Guidelines do not endorse chronic phenazopyridine; patients who have been self-medicating with OTC AZO for years should be redirected to the AUA IC/PBS framework.
Related Articles
- NSAIDs & analgesics — broader analgesic framework including phenazopyridine's position vs NSAIDs and opioids
- UTI treatment antibiotics — definitive therapy that phenazopyridine bridges toward
- UTI suppressive & prophylactic — prevention framework (where phenazopyridine has no role)
- Non-antibiotic UTI prevention
- Local anesthetics — intraurethral and intravesical analgesia for office procedures
- Methylene blue — antidote for phenazopyridine-induced methemoglobinemia
References
1. US Food and Drug Administration. Phenazopyridine Hydrochloride — prescribing information. Updated 2025-09-05.
2. US Food and Drug Administration. Phenazopyridine Hydrochloride — prescribing information. Updated 2022-05-31.
3. Luyts N, Daniluk J, Freitas ACN, et al. "Inhibition of TRPM8 by the urinary tract analgesic drug phenazopyridine." Eur J Pharmacol. 2023;942:175512. doi:10.1016/j.ejphar.2023.175512
4. Zelenitsky SA, Zhanel GG. "Phenazopyridine in urinary tract infections." Ann Pharmacother. 1996;30(7-8):866–868. doi:10.1177/106002809603000727
5. Anger J, Lee U, Ackerman AL, et al. "Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline." J Urol. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860